Posted by Michael Wonder on 24 Feb 2023
Libtayo (cemiplimab) in combination with chemotherapy receives positive CHMP opinion for the treatment of advanced PD-L1 positive non-small cell lung cancer
24 February 2023 - Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy alone.
Regeneron Pharmaceuticals today announced the EMA's CHMP has adopted a positive opinion for Libtayo (cemiplimab) in combination with platinum-based chemotherapy.
